Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.


The proteasome has emerged as an important clinically relevant target for the treatment of hematologic malignancies. Since the Food and Drug Administration approved the first-in-class proteasome inhibitor bortezomib (Velcade) for the treatment of relapsed/refractory multiple myeloma (MM) and mantle cell lymphoma, it has become clear that new inhibitors are… (More)


2 Figures and Tables